Technology Transfer | Helmholtz Munich

From excellence in research to medical solutions.

Our technology transfer includes the development of new preventive measures, innovative diagnostics, medical technologies and sensors, and personalized therapeutics. Helmholtz Munich places particular emphasis on the discovery and development of drugs based on new small molecules, biologics, vaccines, as well as immune-, cellular- and gene therapies.

The basis for new innovations at Helmholtz Munich is the multidisciplinary and internationally excellent biomedical research combined with innovative technologies and disciplines from the fields bioengineering, collection of population-based data and application of digitalization and artificial intelligence. For efficient translation and successful technology transfer, Helmholtz Munich has introduced important measures in recent years and created the necessary infrastructure. These include scientific platforms and expertise in the field of drug discovery and development as well as the establishment of translation centers with clinical partners. An internal funding concept for the systematic further development and validation of innovation projects has led to the establishment of valuable and sustainable project portfolios as a basis for industrial collaborations and new spin-offs.

A dynamic web of entities and people working together to foster and advance new ideas, technologies, and solutions.

Helmholtz Munich is partnering with Deep Science Ventures (DSV) and SPRIND, Germany’s Federal Agency for Disruptive Innovation, to support the Venture Science Doctorate (VSD) – a novel doctoral program designed to train scientists to build…

TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich, has entered its first clinical trial in patients. Following a successful phase 1a trial in healthy volunteers, where the vaccine…

Start of the M1 Munich Medicine Alliance

The M1 Munich Medicine Alliance has officially launched, bringing together the two Munich-based Excellence Universities – Ludwig-Maximilians-Universtiät (LMU) and the Technical University of Munich (TUM) – along with their associated university…

Taconic Biosciences, a global leader in providing animal model solutions and services, entered into an exclusive license agreement with Helmholtz Munich to provide preclinical researchers with advanced CRISPR gene editing services. Through this…

Helmholtz Munich is a partner in four Clusters of Excellence selected for funding under the Excellence Strategy of the German federal and state governments. The projects, each granted a seven-year term, were announced by the German Research…

Angioplasty Procedure: Stent Deployment in a Coronary Artery

A research team from Helmholtz Munich, the Technical University of Munich (TUM) and the TUM University Hospital has developed DeepNeo, an AI-powered algorithm that automates the process of analyzing coronary stents after implantation. The tool…

The Helmholtz Association is pooling its commitment to prevention research with the launch of the Helmholtz Health Prevention Task Force. In a strategy paper published in Nature Medicine, the expert committee outlines initial concepts for more…

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious…

In 2021, a research team led by Prof. Heiko Lickert from Helmholtz Munich discovered the insulin-inhibitory receptor "Inceptor" and its role as a suppressor of the insulin signaling pathway. Now, the researchers have unlocked another, even more…

Life Science Factory Eröffnung Laborsicht

The Life Science Factory has opened its new site on the Helmholtz campus in Munich. Beginning in 2025, around 1,800 square meters of state-of-the-art laboratories and a flexible co-working space will be available for life science start-ups and…

On June 12, 2024, the National Strategy for Gene and Cell Therapies was unveiled at the Futurium in Berlin.

The X-ray of the human brain closeup image

In an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…

In a new collaboration, the Computational Health Center at Helmholtz Munich has teamed up with the global pharmaceutical company Pfizer. The joint initiative, spanning three years, aims to leverage Pfizer's vast knowledge and accumulated data in…

EU Project PerForM-REACT Strengthens Pandemic Preparedness Efforts

On March 11, 2024, the inauguration of the expanded safety laboratory in Augsburg marked a milestone within the EU-funded "PerForM-REACT" project, aimed at enhancing pandemic…

test vitro Hepatitis B HBV to the hand in glove on a blue background

TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase 1a clinical trial is conducted at the Division of…

Fork with measuring tape around on pink background

2023 has changed the way we treat obesity. A new class of drugs, mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), is reshaping medicine and improving many people’s lives globally. GLP-1 drugs do not only induce significant weight loss,…

Innovations and transfer are specifically promoted at Helmholtz Munich.

In collaboration with Helmholtz Munich, Medigene is expanding its portfolio of costimulatory switch proteins in the field of cancer immunotherapy. By expanding the license field, these specialized proteins, initially developed by Helmholtz Munich,…

The Life Science Factory incubator initiated by Sartorius in Göttingen and the top biomedical research center Helmholtz Munich are entering into a strategic partnership to support spin-offs in the life sciences. Within this framework, the Life…

Bayerischer Medizingipfel im TranslaTUM am 17.7.2023

"M1 - Munich Medicine Alliance" established as a strategic alliance for excellence in healthcare in Munich.

The Helmholtz Pioneer Campus was officially inaugurated today under the slogan "ENGINEERING THE FUTURE OF MEDICINE". Commissioning this new state-of-the-art research facility is a significant milestone for young talents in medical research and…

Prof. Reinhard Zeidler about hope in the fight against glioblastoma, the most common and malignant form of brain tumor and how he accelerates the development of antibodies into application.

Medical concept of cancer. 3d illustration of T cells or cancer cells.

Helmholtz Munich and Medigene AG expand their partnership in order to further discover and develop T-cell immunotherapies for solid tumors. Medigene acquired from Helmholtz Munich the exclusive, worldwide rights to the CD40L-CD28 Costimulatory Switch…

Clinical trials are a milestone in the development of safe and effective drugs and therapies. An antibody developed by Helmholtz Munich is now entering a phase 1 clinical trial. Together with the radiopharmaceutical company ITM Isotope Technologies…

Matthias Tschöp, CEO of Helmholtz Munich, talks about translating scientific discoveries into clinical practice, about ambitious targets, and about ideas he acquired during his time in the USA.

The medical technology company Dermagnostix GmbH is a joint spin-off of Helmholtz Munich, the Technical University (TU) Munich and Hahn-Schickard. Its goal: to redefine molecular diagnostics in dermatology. Dermagnostix has now qualified as one of 30…

Panoramic teamwork business join hand together concept, Business team standing hands together, Volunteer charity work. People joining for cooperation success business.

Researchers at Helmholtz Munich are working toward a world without diabetes. They are not doing so alone, but with a network of organizations, hospitals, and pharmaceutical companies. Their goal is to use experts’ knowledge to create something new:…

A team of researchers from Helmholtz Munich, the German Center for Diabetes Research (DZD) and Novo Nordisk have developed a new hormone combination for the future treatment of type 2 diabetes. The scientists have combined the blood sugar-reducing…

A clinical study confirms the success of a novel technology developed by Helmholtz Munich and the Technical University of Munich (TUM) for the evaluation of the treatment of psoriasis. With the new method, doctors can look deeper into the skin of…

Mononucleosis and Epstein-barr virus blood test sample in lab on the white background, laboratory table

The Epstein-Barr virus (EBV) has been known for some time to play a part in a range of diseases. A current US study has now shown a close link between EBV and multiple sclerosis. Scientists at Helmholtz Munich and DZIF are already working on…

Researchers have designed antibodies as novel therapeutic candidates for the treatment of chronic hepatitis B and hepatocellular carcinoma. Their study in human cell cultures and in living mice showed the elimination of antigen-positive cells and…

Pancreatic organoids on newly developed chip platform

A newly engineered organoid on chip platform mimics robustly key features of human pancreas development. This is a stepping stone towards reliable diagnostic solutions for early-stage pancreatic cancer. The study was carried out by an…

A small molecule has entered a novel clinical trial for cancer immunotherapy. The molecule inhibits an enzyme called MALT1 that plays a critical role in suppressing immune reactions against tumor cells. Preclinical studies showed that blocking MALT1…

Helmholtz Zentrum München and Novo Nordisk recently extended their multi-year strategic partnership which aims to identify and jointly develop novel targets and enabling technologies, ultimately supporting the development of innovative medicines for…

3D model Chagas protein blocking molecule

Researchers at Helmholtz Zentrum München and the University of Bochum received this year's Erwin Schrödinger Prize in recognition of their efforts to develop a cure for parasitic diseases such as Chagas disease with a new compound. The prize is…

The Helmholtz Zentrum München teams up with Boehringer Ingelheim in an endeavor to identify novel candidates for anti-obesity treatment.

Antibody, immunoglobulin, Y-shaped protein produced mainly by plasma cells

Large-scale antibody testing against the new coronavirus SARS-CoV-2 could help to obtain reliable data on infection rates. Screening children for early stages of type 1 diabetes in Bavaria, "Fr1da-plus" will now integrate SARS-CoV-2 antibody testing…

Helmholtz Zentrum München and academic partners in the US entered into an exclusive license agreement with Arbormed towards further developing and globally commercializing a potential drug for the treatment of Wilson disease.

Antibodies attack a cancer cell or virus

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has reached a new…

Close-up medical syringe with a vaccine.

Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B. The scientists found that the large amount of…

159

Patent Families

Percent thereof licensed

Spin-Offs

Products

Empowering Innovations

Innovations and transfer are specifically promoted at Helmholtz Munich. A team of experts advises researchers on patent applications as well as on cooperation with industry and the spin-off of high-tech companies.

We research innovative molecules, biologics, vaccines, and immune and cell therapies for effective prevention and treatment of diseases with high unmet medical need.

Our novel biomarkers, diagnostic antibodies, probes, imaging techniques and medical devices support the diagnosis and therapy of personalized medicine and specific treatment and personalized medicine.

We generate cell lines, research antibodies, molecular probes, assays, genetic tools, and artificial intelligence (AI)-based algorithms to strengthen high-level translational research and innovation.

To ensure that acquired know-how and inventions reach society and help patients as quickly as possible, we promote their transfer into sustainable companies and marketable products.

Technology Offers by Helmholtz Munich. Read more

innovationandtranslationspam prevention@helmholtz-munich.de

The Entrepreneurial Life Science Accelerator (ELSA) supports life science start-ups in refining their business concepts, making them market-ready, and accelerating their growth in the shortest time possible.

Learn more

The Life Science Factory in Munich-Neuherberg offers start-ups access to a modern lab space and benefit from a wide range of support services. This new site creates ideal conditions for developing innovative ideas and connecting with other players in the life science community.

Learn more

On This Page

From Lab Bench to Startup: New Doctorate Program Offers Scientists a Venture-Building Path

Therapeutic Vaccine for Chronic Hepatitis B Enters First Clinical Trial in Patients

Start of the M1 Munich Medicine Alliance

License Agreement to Expand its CRISPR/Cas9 Gene Editing Services

Helmholtz Munich Partners in four Clusters of Excellence

AI-Powered Analysis of Stent Healing

Helmholtz Launches Task Force to Strengthen Prevention Research

Start-up EBViously founded

Inceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies

Life Science Factory Expands: New Innovation Hub Opens in Munich in Cooperation with Helmholtz Munich

Helmholtz Munich contributes to the National Strategy for Gene and Cell Therapies

First Patient Administered New Drug for Brain Tumor Treatment

Helmholtz Munich and Pfizer Join Forces to Advance Target Discovery and Precision Medicine through Deep Learning

Pandemic Preparedness: New High-Tech Laboratory in Augsburg

Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial

Science Has Named GLP-1 Drugs the Breakthrough of the Year

Empowering Innovations: From the Idea to Impactful Products

Medigene Expands Helmholtz Munich IP Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types

Life Science Factory to Open a New Location at Helmholtz Munich in 2024

Helmholtz Munich strengthens healthcare excellence in Munich through strategic alliance

The Future of Medicine: Helmholtz Munich Opens Innovation Campus

Targeted Antibody Therapy Against Brain Tumor Glioblastoma

Helmholtz Munich partners with Medigene to accelerate Tumor Therapy

Targeting Brain Tumors: New Drug Candidate in Clinical Trial

"A startup can be just as big a success as a Leibniz Prize!"

Dermagnostix receives EIC funding of 2,5 million euros

Our Partnerships for a World Without Diabetes

New Drug Candidate Developed to Treat Type 2 Diabetes

Under the Skin: Better Treatment of Psoriasis by Scanning Light and Sound

Epstein-Barr Virus: Helmholtz Munich and DZIF Are Working on a Vaccine

Bioengineering Meets Hepatitis B: Researchers Design Promising Novel Therapeutic Candidates

Researchers Engineer an Organoid on Chip Platform to Recapitulate Pancreatic Organoids

First-in-class Cancer Immunotherapy Drug in Clinical Trial

Helmholtz Zentrum München and Novo Nordisk extended their research collaboration in metabolic diseases

Helmholtz Zentrum München Is the Recipient of the 2020 Erwin Schrödinger Prize

Research Cooperation between Helmholtz Zentrum München and Boehringer Ingelheim

Established Study Combines Early Detection of Type 1 Diabetes With Sars-Cov-2 Antibody Testing in Thousands of Children

Drug Candidate for Wilson Disease to Be Further Developed

Collaboration and Option Agreement with Medigene

Hepatitis B: New Therapeutic Approach May Help to Cure Chronic Hepatitis B Infection

Empowering Innovations

Technology Portfolio

Therapeutics

Diagnostics and Medical Devices

Technologies

Spin-Offs

Technology Offers

Contact

ELSA

Start-Up Incubator